natgillin/translations-raw huggingface dataset:
If you experience prolonged bleeding when taking Plavix If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel HCS Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se krvavitev ustavi.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
V študiji CURE je 823 (6,6%) bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8.
Drugi aleli, povezanimi z odstotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Po enkratnem in večkratnih peroralnih odmerkih po 75 mg na dan se klopidogrel hitro absorbira
What Clopidogrel HCS is and what it is used for
Kaj je zdravilo Klopidogrel HCS in za kaj ga uporabljamo
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance je predstavljen v Modulu 1.8.1. pridobitve dovoljenja za promet z zdravilom, vzpostavljen in deluje,
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician's decision was based on the patient's unwillingness to take VKA.
Triinsedemdeset odstotkov (73 %) bolnikov, vključenih v študijo ACTIVE-A, je bilo neprimernih za prejemanje VKA po zdravnikovi oceni, nezmožnosti upoštevanja kontrol INR (internacionalnega normaliziranega razmerja), nagnjenosti k padcem ali poškodbe glave, ali specifičnega tveganja krvavitev; pri 26 % bolnikov je zdravnikova odločitev temeljila na tem, da bolnik ni želel jemati
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel HCS and acetylsalicylic acid for this condition.
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Klopidogrel HCS in acetilsalicilne kisline.
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section
• Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 2
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics.
Populacijo bolnikov je sestavljalo 27,8% žensk, 58,4% bolnikov starost ≥ 60 let (26% ≥ 70 let ) in 54,5% bolnikov, ki so dobivali fibrinolitike.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
B. POGOJI ALI OMEJITVE GLEDE OKRBE IN UPORABE
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel HCS.
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden vzamete zdravilo Klopidogrel HCS.
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
Študija ACTIVE-A (n = 7.554) je bila multicentrična, randomizirana, dvojno slepa, s placebom kontrolirana študija, ki je primerjala klopidogrel 75 mg/dan + ASA (n = 3.772) in placebo + ASA
In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
Pediatrična populacija V študiji povečevanja odmerka, ki je zajela 86 novorojenčkov ali dojenčkov, starih do 24 mesecev, s tveganjem tromboze (PICOLO), so klopidogrel ocenili v zaporednih odmerkih 0,01, 0,1 in 0,2 mg/kg pri novorojenčkih in dojenčkih ter 0,15 mg/kg samo pri novorojenčkih.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY, COMMIT in ACTIVE_A, so predstavljeni v nadaljevanju.
What Clopidogrel HCS is and what it is used for What you need to know before you take Clopidogrel HCS How to take Clopidogrel HCS Possible side effects
Kaj je zdravilo Klopidogrel HCS in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzel zdravilo Klopidogrel HCS Kako jemati zdravilo Klopidogrel HCS
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC04.
Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
Your doctor should have prescribed Clopidogrel HCS plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Zdravnik naj bi vam predpisal zdravilo Klopidogrel HCS skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
Pri bolnikih, ki so se zdravili do pet dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6%% za klopidogrel in ASA in 6,3%% za placebo in ASA.
The incidence of severe cases was similar for clopidogrel and ASA.
Incidenca hujših primerov krvavitev je bila podobna za klopidogrel in za ASA
Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to clopidogrel*
(vazospastična alergijska angina / alergijski miokardni infarkt) v okviru preobčutljivostne reakcije zaradi klopidogrela*
If you become pregnant while taking Clopidogrel HCS, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Če med zdravljenjem z zdravilom Klopidogrel HCS zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed clopidogrel in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali klopidogrel v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
• odraslih bolnikih z akutnim koronarnim sindromom: Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
Contents of the pack and other information What Clopidogrel HCS contains
Vsebina pakiranja in dodatene informacije Kaj vsebuje zdravilo Klopidogrel HCS
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan pri osebah s hudo ledvično boleznijo (kreatininski očistek 5-15 ml/min) inhibicija z ADP-jem sprožene agregacije trombocitov manjša (25%%) od tiste, opažene pri zdravih osebah.Vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so jemale 75 mg klopidogrela na dan.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Eliminacija Po peroralnem odmerku s 14C označenega klopidogrela pri človeku se ga je v 120-urnem intervalu po odmerjanju približno 50%% izločilo s sečem in približno 46% z blatom.
The safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Trombolitiki Varnost sočasnega jemanja klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ovrednotena pri bolnikih z akutnim miokardnim infarktom.
Other medicines and Clopidogrel HCS
Druga zdravila in zdravilo Klopidogrel HCS
Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.
Glavobol, razjeda na želodcu, bruhanje, slabost, zaprtost, preveč plinov v želodcu ali črevesju, izpuščaji, srbenje, omotica, občutek mravljinčenja in otopelosti..
HCS bvba, H. Kennisstraat 53, B 2650 Edegem, Belgium
Imetnik dovoljenja za promet: HCS bvba, H. Kennisstraat 53, B 2650 Edegem, Belgija
Driving and using machines Clopidogrel HCS is unlikely to affect your ability to drive or to use machines.
Ni verjetno, da bi zdravilo Klopidogrel HCS vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
- efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, - carbamazepine, a medicine to treat some forms of epilepsy, - moclobemide, medicine to treat depression, - repaglinide, medicine to treat diabetes, - paclitaxel, medicine to treat cancer.
- efavirenz, zdravilo za zdravljenje infekcij z virusom HIV (virus humane imunske pomanjkljivosti), - karbamazepin, zdravilo za zdravljenje nekaterih oblik epilepsije, - moklobemid, zdravilo za zdravljenje depresije, - repaglinid, zdravilo za zdravljenje sladkorne bolezni, - paklitaksel, zdravilo za zdravljenje raka.
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of food.
Zlatenica, huda bolečina v trebuhu z bolečino v hrbtu ali brez nje, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije (na primer, splošni občutek toplote z nenadnim nelagodjem do nezavesti), oteklina v ustih, mehurji na koži, kožna alergija, vnetje v ustih (stomatitis), znižanje krvnega tlaka, zmedenost, halucinacije, bolečine v sklepih, bolečine v mišicah, motnje v okušanju ali izguba okusa hrane.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
Alel CYP2C19*1 ustreza polno funkcionalni presnovi, medtem ko alela CYP2C19*2 in CYP2C19*3
Clopidogrel HCS contains hydrogenated castor oil
Zdravilo Klopidogrel HCS vsebuje hidrogenirano ricinusovo olje
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Skupno 99,7% bolnikov je dobivalo fibrinolitike (fibrinsko specifične: 68,7%, nefebrinsko specifične: 31,1%), 89,5% heparin, 78,7% zaviralce adrenergičnih receptorjev beta, 54,7% zaviralce ACE in 63 % statine.
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
V TRITON-TIMI 38 in 3 kohortnih študijah (Collet, Sibbing, Giusti) je imela kombinirana skupina bolnikov, ki so bili ali srednji ali slabi metabolizatorji, večji delež kardiovaskularnih dogodkov (smrt,
Very rare side effects (may affect up to 1 in 10,000 people):
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov):
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8)
Incidenca klinično pomembnih krvavitev je bila podobna tisti, ki so jo opazili pri sočasnem jemanju trombolitikov in heparina ter ASA (glejte poglavje 4.8).
• Tablet coating: Polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
- Obloga tablete: polivinilalkohol, titanov dioksid (E171), rdeči železov oksid (E172), rumeni železov oksid (E172), smukec, in makrogol 3000.
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
V klinični študiji, na zdravih prostovoljcih je sočasno jemanje klopidogrela in naproksena povečalo prikrito krvavitev iz prebavil.
Then, the recommended dose is one 75 mg tablet of Clopidogrel HCS per day as described above.
Nato je priporočeni odmerek ena 75-mg tableta zdravila Klopidogrel HCS na dan, kot je opisano zgoraj.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =
Pri bolnikih, ki so bili v preizkušanje vključeni samo na podlagi nedavnega MI, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT: -4%%;
CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4.
CYP, vključno s CYP1A2, CYP2B6 in CYP3A4.
Clopidogrel HCS contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
Zdravilo Klopidogrel HCS vsebuje klopidogrel in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
(hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis, eozinofilna pljučnica
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3%; IZ: 24,3%, 57,5%) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT =18,2%; IZ: 6,5%, 28,3%).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Pri analizi podskupin glede na vključitveni pogoj (MI, ishemična kap in PAD) je bila korist (doseganje statistične značilnosti pri p = 0,003) največja pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi MI) (zmanjšanje RT: =23,7%; IZ: 8,9 do 36,2), in manjša (ni bila pomembno drugačna kot pri ASA) pri bolnikih s kapjo (zmanjšanje RT: 7,3%; IZ: -5,7 do 18,7 /p =
How to store Clopidogrel HCS Contents of the pack and other information
Shranjevanje zdravila Klopidogrel HCS Vsebina pakiranja in dodatne informacije
The patient population included 19.7% women and 29.2% patients ≥65 years.
Populacijo bolnikov je sestavljalo 19,7 % žensk in 29,2 %
In a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
V klinični študiji na zdravih osebah zaradi jemanja klopidogrela ni bilo treba spremeniti odmerka heparina, pa tudi učinek heparina na koagulacijo se ni spremenil.
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
V celoti je bil klopidogrel v odmerku 75 mg/dan v študiji CAPRIE, primerljiv z ASA v odmerku 325 mg/dan, ne glede na starost,
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
V celoti je 23,0 % bolnikov prejemalo antiaritmike, 52,1 % blokatorje beta, 54,6 %
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
ki je potreben za zaustavitev krvavitve, daljši kot ponavadi, in da morajo svojemu zdravniku poročati o kakršnikoli neobičajni krvavitvi (o mestu ali trajanju).
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Plavix.
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta,
You have been prescribed Clopidogrel HCS to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or
Zdravilo Klopidogrel HCS vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate otrdele arterije (znano tudi kot ateroskleroza), in
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel HCS (4 tablets of 75 mg) once at the start of treatment.
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da enkrat 300 mg zdravila Klopidogrel HCS (štiri 75-mg tablete).
The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 109/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds.
mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov < 50 x 109/l), potreba po klopidogrelu ali peroralnih antikoagulantih ali intoleranca za katero od obeh snovi.
If you take more Clopidogrel HCS than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Zaradi povečanega tveganja za krvavitev se posvetujte s svojim zdravnikom ali z medicinskim osebjem na najbližjem bolnišničnem oddelku za nujno zdravniško pomoč.
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions').
• znaki jetrnih težav, npr. porumenelost kože in/ali oči (zlatenica), ki so lahko povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2
What Clopidogrel HCS looks like and contents of the pack
Izgled zdravila Klopidogrel HCS in vsebina pakiranja
If you forget to take Clopidogrel HCS
Če ste pozabili vzeti zdravilo Klopidogrel HCS
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Tako kot druge antitrombotike tudi klopidogrel previdno uporabljamo pri bolnikih, pri katerih zaradi poškodbe, kirurškega posega ali drugih patoloških stanj obstaja tveganje za povečano krvavitev, in pri bolnikih, ki so na zdravljenju z ASA, s heparinom, z zaviralci glikoproteina IIb/IIIa ali z nesteroidnimi protivnetnimi zdravili (NSAID), vključno z zaviralci ciklooksigenaze-2 (COX-2) ali s selektivnimi zaviralci privzema serotonina (SSRI) ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve,
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking
Če katerokoli od spodaj navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika,
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with
(toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), akutna generalizirana eksantemska pustuloza (AGEP), angioedem, z zdravili povzročen sindrom preobčutljivosti
If you stop taking Clopidogrel HCS
Če ste prenehali jemati zdravilo Klopidogrel HCS
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen (PAD) Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (<35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
What you need to know before you take Plavix Do not take Plavix:
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel HCS Ne jemljite zdravila Klopidogrel HCS:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).